Trials to watch: Three major catalysts in Alzheimer’s disease
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms of action.
30 September 2025
30 September 2025
While Lilly and Eisai/Biogen have validated the amyloid theory, there is an unmet need for drugs with alternative mechanisms of action.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.